Novogen comments on recent share price rise Novogen today released the following statement by Dr Graham Kelly, CEO of Novogen Ltd. “The Company is unable to provide an explanation for the 45% rise in its ADR stock overnight on the NASDAQ exchange, other than the observation that is followed an article that appeared yesterday in the US press that speculated on the future of the Company. That article, in part, speculated on the possibility that the Company was engaged in discussions with another party in relation to its super benzopyran drug technology. As was flagged in the 2013 Annual Report released recently, the Company is seeking to establish a structure that will facilitate its goal of delivering personalized chemotherapy on an individual patient basis. The Company currently is working towards establishing such a structure that will be announced when and if it is established. Until then, the Company is not in any position to provide any more
NRT Price at posting:
22.0¢ Sentiment: None Disclosure: Held
